Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | PDGFRB | P09619 | 10/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 10/20 | 0.56 |
| ▸ | PDE4A | P27815 | 4/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.47 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1010778 | 0.84 | ALDH1A1 (1.00) | KDM4EALDH1A1SMN1; SMN2PDGFRBPDGFRA | |
| SCHEMBL27987996 | 0.80 | PDGFRB (0.61) | PDGFRBPDGFRAPDE4APDE4BPDE4C | |
| SCHEMBL31352747 | 0.76 | ALDH1A1 (0.81) | KDM4EALDH1A1SMN1; SMN2PDGFRBPDGFRA | |
| SCHEMBL2259848 | 0.75 | PDGFRB (0.54) | PDGFRBPDGFRA | |
| SCHEMBL2259850 | 0.75 | PDGFRB (0.54) | PDGFRBPDGFRA | |
| SCHEMBL1401333 | 0.74 | PDGFRB (0.94) | PDGFRBPDGFRATLR9TLR7 | |
| SCHEMBL5177457 | 0.74 | KDM4E (0.54) | KDM4EALDH1A1SMN1; SMN2PDGFRBPDGFRA | |
| SCHEMBL8501994 | 0.73 | KDM4E (0.77) | KDM4EALDH1A1SMN1; SMN2PDGFRBPDGFRA | |
| SCHEMBL14258169 | 0.73 | SMN1; SMN2 (0.77) | KDM4EALDH1A1SMN1; SMN2PDGFRBPDGFRA | |
| SCHEMBL8204138 | 0.73 | PDE4A (0.65) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| EP-2024342-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | Pfizer Products Incorporated (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007125405-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | KDM4E 2041/4885ALDH1A1 1098/4885SMN1; SMN2 2141/4885 |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | KDM4E 2041/4885ALDH1A1 1098/4885SMN1; SMN2 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.